Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763429 | 0.90 | MEN1 (0.41) | LMNATSHRHTT | |
| SCHEMBL404392 | 0.82 | FDPS (0.42) | — | |
| SCHEMBL5780510 | 0.81 | ALDH1A1 (0.38) | LMNA | |
| SCHEMBL643420 | 0.81 | MAPT (0.38) | CYP19A1TSHR | |
| SCHEMBL5662615 | 0.81 | LOXL2 (0.35) | HRH3 | |
| SCHEMBL11503093 | 0.80 | RXRA (0.41) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL6370660 | 0.78 | MEN1 (0.32) | HTT | |
| SCHEMBL13685302 | 0.77 | LPL (0.41) | — | |
| SCHEMBL6370318 | 0.77 | L3MBTL1 (0.43) | LMNAHTT | |
| SCHEMBL6376616 | 0.76 | PPARA (0.44) | ALOX5LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3040333-A1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | Novartis AG (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| WO-2004111058-A1 | HETERORYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | TAAR1 4433/4885PYCR1 3623/4885MME 4110/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | TAAR1 4151/4885PYCR1 2713/4885MME 4105/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | TAAR1 4718/4885PYCR1 647/4885MME 672/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | TAAR1 4521/4885PYCR1 3504/4885MME 890/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | TAAR1 4805/4885PYCR1 4483/4885MME 3298/4885 |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | TAAR1 2398/4885PYCR1 2688/4885MME 3547/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | TAAR1 4521/4885PYCR1 3504/4885MME 890/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | TAAR1 4705/4885PYCR1 2892/4885MME 3699/4885 |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | TAAR1 2398/4885PYCR1 2688/4885MME 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.